Cancer Specialty
Conference Coverage
- ASCO
- AACR 2024
- ASCO GI 2024
- ASH 2023
- SABCS 2023
- MOASC
- ASCO 2023

Advertisement

X (Twitter) LinkedIn Facebook

X (Twitter) LinkedIn Facebook

Cancer Specialty
Conference Coverage
- ASCO
- AACR 2024
- ASCO GI 2024
- ASH 2023
- SABCS 2023
- MOASC
- ASCO 2023

Home » Servier’s R&D Efforts in Oncology #ASH #ASH19

News

Servier’s R&D Efforts in Oncology #ASH #ASH19

By EditorJanuary 17, 2020No Comments1 Min Read

Twitter LinkedIn Facebook Email

Share

Twitter LinkedIn Facebook Email

Patrick Therasse, MD of Servier Group discusses Servier’s R&D efforts in oncology.

Follow on X (Twitter) Follow on LinkedIn Follow on Facebook Follow on Google News

Share. Twitter LinkedIn Facebook Email

Related Posts

MEGA-CRISPR: RNA Editing Pioneering the Future of Precision Cancer Therapy

News 4 Mins Read

Honoring Dr. Krystal Cascetta, Devoted Cancer Researcher

News 2 Mins Read

Nivolumab and Pembrolizumab Dosing Intervals Optimizing Cancer Treatment

News 3 Mins Read

Advertisement Sidebar

Recent Posts

BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Lead to Longevity Leaps?
Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results
Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer
Metastatic Breast Cancer: Trastuzumab (Herceptin) Factors for Long-Term Remission in HER2 negative
Breast Cancer New Nemeses: CDK4/6 Inhibitors Rave Against Recurrence, But Have They Crashed the EBC Party in NATALEE & monarchE’s Real-World Dance-Off?

Connect With Us on Social

Facebook
Twitter
LinkedIn

X (Twitter) LinkedIn Facebook

© 2024 Copyright Protected Medicus Networks, Inc..

Type above and press Enter to search. Press Esc to cancel.